Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements - Viracta (Details)

v3.24.0.1
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
 12 Months Ended
Oct. 30, 2023
USD ($)
Mar. 22, 2021
USD ($)
item
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs     $ 14,650 $ 8,000
Short-term royalty and commercial payment receivables     14,215 $ 2,366
Viracta        
Agreements        
Reduction in long-term royalty receivable balance due to receipt of payment     5,000  
Viracta | Royalty Purchase Agreement        
Agreements        
Number of drug candidates | item   2    
Payments of consideration under RPAs, AAAs and CPPAs   $ 13,500    
Maximum amount of potential milestones, potential royalties on sales and other payments receivable   54,000    
Amount of maximum consideration retained   5,000    
Maximum amount of potential regulatory and commercial milestones receivable   57,000    
Acquisition of royalty and commercial payment receivables, Long-Term   $ 13,500    
Amount of milestone payments earned under agreement $ 5,000      
Reduction in long-term royalty receivable balance due to receipt of payment $ 5,000      
Short-term royalty and commercial payment receivables     0  
Amount of allowance for credit losses     $ 0